Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.
Fundamentals
Mkt Cap
$11.02B
Volume
-
52W High
$615.00
52W Low
$393.61
PE Ratio
-36.62
Avg. Volume
225,384.34
EPS (Annual)
-$12.85
P/B
20.80
Rev/Employee
$1,047,434.97
Earnings
Nov 04
51
Neutral Sentiment
How do you feel about MDGL?
sarkar20
$MDGL
Most of the times this kind if manipulation (without any news) is seen before BO!! Hope this is the case for MDGL too, BO soon?
1
2
balzofsteel
$MDGL The company is a potential takeover target
One thing that could set the stock's price soaring is a takeover attempt by a larger pharmaceutical company.
Madrigal's combination of a differentiated asset in Rezdiffra, strong cash reserves ($838.9 million as of the second quarter), and a pipeline in development makes it an attractive target for larger pharmaceutical firms seeking to enter the metabolic liver disease space. The global research and development (R&D) landscape is increasingly characterized by partnerships and acquisitions, as companies seek to fast-track access to novel therapies, a mindset that continues to accelerate biotech M&A across the healthcare sector.
Rezdiffra's U.S. patent protection until 2045 and its 2025 approval in the European Union provide a durable competitive moat. A takeover would allow a larger firm to capitalize on Rezdiffra's commercial momentum while mitigating the risks of in-house R&D.
1
3
Wallst45
$MDGL CITI INITIATES MADRIGAL PHARMACEUTICALS COVERAGE WITH BUY RATING AND $725 PT
The firm believes the company's Rezdiffra is being underappreciated at current share levels. The launch has exceeded expectations and "blockbuster status is imminent"
4
1986iamwallstreet
$MDGL undervalued, when that huge buyout come this will be trending and people will be saying nobody told them about this lol
4
balzofsteel
$MDGL Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725
Benzinga 2026-09-23T11:04:00-04:00
Citigroup analyst Eric Joseph initiates coverage on Madrigal Pharmaceuticals (MDGL.NaE) with a Buy rating and announces Price Target of $725
3
sarkar20
$MDGL
I agree, I think it is in final stages, soon this beauty will get a BO!! 900 coming soon, imo!!
3
forprofit12
$MDGL and? Price is still pathetic. Regret adding this. The lost opportunity cost on this one is huge.
2
forprofit12
$MDGL volume is down as there are no near term catalysts. Wouldn’t mind a buyout though.
2
Whiskeyunderthebed
$MDGL Has nothing to do with it- sector rotation and money are leaving health care sector-
1
Live2ride
$MDGL Getting close to another swing trade. MDGL.... come on downnnnnnn. Your the next contestant on the Price is Right.
1
sarkar20
$MDGL
I guess there is no BO and it seems not good things in future the way stock price is moving these days!!